ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Oppenheimer

Oppenheimer assumed coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research report released on Friday morning, Marketbeat reports. The firm issued an outperform rating and a $15.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on PRQR. Raymond James raised shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $6.00 to $14.00 in a research report on Tuesday, October 29th. JMP Securities reissued a “market outperform” rating and set a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. StockNews.com lowered ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Finally, Chardan Capital reissued a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.83.

ProQR Therapeutics Trading Down 7.6 %

ProQR Therapeutics stock opened at $2.42 on Friday. The stock has a market cap of $197.67 million, a PE ratio of -7.56 and a beta of 0.30. The stock has a 50-day moving average price of $3.23 and a 200 day moving average price of $2.51. ProQR Therapeutics has a 52 week low of $1.61 and a 52 week high of $4.62.

Institutional Investors Weigh In On ProQR Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Privium Fund Management B.V. lifted its stake in shares of ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after purchasing an additional 51,663 shares in the last quarter. OneDigital Investment Advisors LLC lifted its position in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).